Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Parkinson's Disease

Free Subscription Articles published in Neurology Retrieve available abstracts of 127 articles: HTML format

Single Articles

March 2026
1. BENARROCH E
   How Are Synaptic Vesicle Exocytosis and Endocytosis Affected in Parkinson Disease?
   Neurology. 2026;106:e214770.
   PubMed     Abstract available
   
   
   
2. AHN SH, Kim DH, Park J, Yoon J, et al
   Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality: A Competing Risk Analysis Approach.
   Neurology. 2026;106:e214722.
   PubMed     Abstract available
   
   
   
3. URSO D, Logroscino G
   Dynamic Smoking Patterns and Risk of Parkinson Disease.
   Neurology. 2026;106:e214651.
   PubMed    
   
   
   February 2026
4. DIAZ-GALVAN P, Franco-Rosado P, Silva-Rodriguez J, Castro-Labrador S, et al
   Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease.
   Neurology. 2026;106:e214455.
   PubMed    
   
   
   
5. SUN Y, Na HK, Jeon S, Ye BS, et al
   Cerebral Perfusion and Motor Deficits in Drug-Induced Parkinsonism: A Dual-Phase (18)F-FP-CIT PET Study.
   Neurology. 2026;106:e214573.
   PubMed     Abstract available
   
   
   
6. GERMAN A, Grotemeyer A, Rothhammer V, Doerfler A, et al
   Pearls & Oy-sters: Reversible Leukoencephalopathy and Parkinsonism Due to CNS Involvement in Cryoglobulinemia.
   Neurology. 2026;106:e214622.
   PubMed     Abstract available
   
   
   
7. THATIKALA A, Boddu AV, Nayar D, Virmani T, et al
   Pearls & Oy-sters: Hereditary Spastic Paraplegia Type 15 Presenting as Juvenile Onset Levodopa-Responsive Parkinsonism.
   Neurology. 2026;106:e214514.
   PubMed     Abstract available
   
   
   
8. COUGHLIN DG, Adler CH, Barbosa W, Feuerstein J, et al
   CSF alpha-Synuclein Seed Amplification Assays and Skin Immunofluorescence: Clinical Applications, Research Opportunities, and Knowledge Gaps.
   Neurology. 2026;106:e214648.
   PubMed     Abstract available
   
   
   January 2026
9. TSUKITA K, Kikuya A, Yoshimura K, Nakanishi E, et al
   Temporal Dynamics and Cross-Sectional and Longitudinal Factors Associated With Motor Reserve and Outcome in Patients With Parkinson Disease.
   Neurology. 2026;106:e214475.
   PubMed     Abstract available
   
   
   
10. LI CH, Fan SP, Chen PS, Chang YY, et al
    Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.
    Neurology. 2026;106:e214406.
    PubMed     Abstract available
    
    
    
11. CONTI M, Mascioli D, Simonetta C, Ferrari V, et al
    Clinical, Biological, and Functional Connectivity Profile of Patients With De Novo Parkinson Disease Who Are APOE epsilon4 Carriers.
    Neurology. 2026;106:e214449.
    PubMed     Abstract available
    
    
    November 2025
12. ORSO B, Mattioli P, Fama F, Massa F, et al
    Uncovering Clinical and Functional Neuroimaging Characteristics of Overt Stage Phenotypes Within the alpha-Synucleinopathy Spectrum.
    Neurology. 2025;105:e214253.
    PubMed     Abstract available
    
    
    
13. BORGES PGLB, Qureshi Q, Hammer LH, Cajigas I, et al
    Effect of Motor Imagery on Tremor in a Patient With Parkinson Disease Undergoing Intraoperative Testing.
    Neurology. 2025;105:e214246.
    PubMed    
    
    
    
14. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    PubMed     Abstract available
    
    
    
15. AVENALI M, Artusi CA, Cilia R, Giannini G, et al
    Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant.
    Neurology. 2025;105:e214036.
    PubMed     Abstract available
    
    
    October 2025
16. PERSICO M, Esper CD
    Can Intrinsic Capacity Help Identify Those at Risk of Parkinson Disease?
    Neurology. 2025;105:e214242.
    PubMed    
    
    
    
17. HU W, Tian G, Wang JN, Ma YB, et al
    Intrinsic Capacity Defined Using 4 Domains, Genetic Risk, and Incident Parkinson Disease: A Prospective Cohort Study.
    Neurology. 2025;105:e214144.
    PubMed     Abstract available
    
    
    
18. KRZYZANOWSKI B, Beyene KM, Turner JR, Racette BA, et al
    Ambient Trichloroethylene Exposure and Parkinson Disease Risk in Medicare Beneficiaries.
    Neurology. 2025;105:e214174.
    PubMed     Abstract available
    
    
    
19. DORSEY ER, Tanner CM
    Trichloroethylene and Parkinson Disease.
    Neurology. 2025;105:e214245.
    PubMed    
    
    
    
20. DELVA A, Fereshtehnejad SM, Vo A, Yao CW, et al
    Evolution of Motor and Nonmotor Characteristics in an Idiopathic/Isolated REM Sleep Behavior Disorder Cohort.
    Neurology. 2025;105:e214108.
    PubMed     Abstract available
    
    
    
21. AYRAL V, Pastor-Bernier A, Daneault V, Tremblay C, et al
    Association of DTI-ALPS Glymphatic Index With Differential Phenoconversion in Isolated REM Sleep Behavior Disorder: A Multi-Cohort MRI Study.
    Neurology. 2025;105:e214042.
    PubMed     Abstract available
    
    
    September 2025
22. ZHANG X, Wang J, Dove A, Yu T, et al
    Metabolic Syndrome and Incidence of Parkinson Disease: A Community-Based Longitudinal Study and Meta-Analysis.
    Neurology. 2025;105:e214033.
    PubMed     Abstract available
    
    
    
23. XUAN Z, Pan Z, Ma C, Lin X, et al
    Reader Response: Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2025;105:e210094.
    PubMed    
    
    
    
24. CHAHINE L, Rosso AL, Troidl I, Ganguli M, et al
    Features of Prodromal Parkinson Disease and Dopaminergic Neurotransmission in Community-Dwelling Older Adults.
    Neurology. 2025;105:e214037.
    PubMed     Abstract available
    
    
    
25. SCHULZ RS, Rist PM, Kurth T
    Author Response: Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2025;105:e210158.
    PubMed    
    
    
    
26. GANESH A, Galetta SL
    Editors' Note: Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2025;105:e214084.
    PubMed    
    
    
    
27. AITA SL, Roth RM
    Much Ado About Nothing? Midlife Vascular Risk Factors and Incident Parkinson Disease.
    Neurology. 2025;105:e214127.
    PubMed    
    
    
    
28. JOHRI M, Morrill V, Okine DN, Huang X, et al
    Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia: The ARIC Study.
    Neurology. 2025;105:e213931.
    PubMed     Abstract available
    
    
    
29. GONZALEZ-ESCAMILLA G, Groppa S
    MRI-Based Evidence of Regular Physical Activity's Impact on Brain Networks for Modifying Disease Courses in Parkinson Disease.
    Neurology. 2025;105:e214059.
    PubMed    
    
    
    
30. DIAZ-GALVAN P, Franco-Rosado P, Silva-Rodriguez J, Castro-Labrador S, et al
    Association of Physical Exercise With Structural Brain Changes and Cognitive Decline in Patients With Early Parkinson Disease.
    Neurology. 2025;105:e213932.
    PubMed     Abstract available
    
    
    August 2025
31. TUOMINEN JA, Riise T, Romanowska J, Flores-Torres MH, et al
    Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation.
    Neurology. 2025;105:e213783.
    PubMed     Abstract available
    
    
    
32. COLOSIMO C, Marsili L
    It Is Time for Drug Repurposing in Parkinson Disease.
    Neurology. 2025;105:e213972.
    PubMed    
    
    
    June 2025
33. WANG P, Chen X, Na M, Flores-Torres MH, et al
    Long-Term Consumption of Ultraprocessed Foods and Prodromal Features of Parkinson Disease.
    Neurology. 2025;104:e213562.
    PubMed     Abstract available
    
    
    
34. MARAKI MI, Scarmeas N
    Fast Food, Slow Damage: The Role of Ultraprocessed Foods in Parkinson Disease.
    Neurology. 2025;104:e213684.
    PubMed    
    
    
    
35. YOUNG CB, Cholerton B, Smith AM, Shahid-Besanti M, et al
    The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
    Neurology. 2025;104:e213648.
    PubMed    
    
    
    May 2025
36. CHEN CC, Chiu JY, Tan AH, Toh TS, et al
    Investigating Plasma Metabolomics and Gut Microbiota Changes Associated With Parkinson Disease: A Focus on Caffeine Metabolism.
    Neurology. 2025;104:e213592.
    PubMed     Abstract available
    
    
    
37. BENARROCH E
    What Are Current Concepts on the Functional Organization of the Globus Pallidus Externus and Its Potential Role in Parkinson Disease?
    Neurology. 2025;104:e213623.
    PubMed    
    
    
    
38. POSTUMA RB
    Having Second Thoughts About Parkinson Diagnosis.
    Neurology. 2025;104:e213594.
    PubMed    
    
    
    
39. RATY V, Kuusimaki T, Majuri J, Vahlberg T, et al
    Stability and Accuracy of a Diagnosis of Parkinson Disease Over 10 Years.
    Neurology. 2025;104:e213499.
    PubMed     Abstract available
    
    
    
40. GANGULY J, Banerjee S, Basu P, Mukherjee S, et al
    Teaching Video NeuroImage: String Hallucinations in Parkinson Disease.
    Neurology. 2025;104:e213611.
    PubMed     Abstract available
    
    
    April 2025
41. SANCHEZ E, Coughlan GT, Wilkinson T, Ramirez J, et al
    Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.
    Neurology. 2025;104:e213438.
    PubMed     Abstract available
    
    
    March 2025
42. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2025;104:e213392.
    PubMed    
    
    
    
43. COUGHLIN DG, Shifflett B, Farris CM, Ma Y, et al
    alpha-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
    Neurology. 2025;104:e210279.
    PubMed     Abstract available
    
    
    
44. PALERMO G, Francesconi A, Bellini G, Morganti R, et al
    Involvement of the Nigrostriatal Pathway in Patients With Idiopathic Normal Pressure Hydrocephalus and Parkinsonism.
    Neurology. 2025;104:e213352.
    PubMed     Abstract available
    
    
    
45. LE HERON C, Horne KL, Macaskill MR, Livingston L, et al
    Author Response: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e209958.
    PubMed    
    
    
    
46. ZHANG X, Zhang Y, Ding C, Yang J, et al
    Reader Response: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e209812.
    PubMed    
    
    
    
47. GANESH A, Galetta SL
    Editors' Note: Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2025;104:e213339.
    PubMed    
    
    
    February 2025
48. YI MY, Cheng S, Chandra AA, Farkas N, et al
    Teaching Video NeuroImage: Methamphetamine-Induced Basal Ganglia Toxicity Presenting as Parkinsonism.
    Neurology. 2025;104:e213365.
    PubMed    
    
    
    
49. ISONAKA R, Sullivan P, Goldstein DS
    Pathophysiological Significance of alpha-Synuclein in Sympathetic Nerves: In Vivo Observations.
    Neurology. 2025;104:e210215.
    PubMed     Abstract available
    
    
    January 2025
50. DE BARTOLO MI, Ojha A, Leodori G, Piervincenzi C, et al
    Association of Early fMRI Connectivity Alterations With Different Cognitive Phenotypes in Patients With Newly Diagnosed Parkinson Disease.
    Neurology. 2025;104:e210192.
    PubMed     Abstract available
    
    
    
51. KOCH MW, Kalia LV, Sarna JR, Wile D, et al
    Feasibility of Simon 2-Stage Futility Trials in Early Parkinson Disease: Analysis of the PRECEPT and DATATOP Trial Datasets.
    Neurology. 2025;104:e210079.
    PubMed     Abstract available
    
    
    
52. ZIEGLER A, Schmid M
    Efficient Study Designs for the Early-Stage Evaluation of Disease-Modifying Treatments in Parkinson Disease.
    Neurology. 2025;104:e210218.
    PubMed    
    
    
    December 2024
53. YOO HS, Lee YG, Sohn YH, Yun M, et al
    Association of Relative Brain Hyperperfusion Independent of Dopamine Depletion With Motor Dysfunction in Patients With Parkinson Disease.
    Neurology. 2024;103:e210077.
    PubMed     Abstract available
    
    
    
54. YOO HS, Kim HK, Na HK, Kang S, et al
    Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and Cognitive Deficits in Patients With Parkinson Disease.
    Neurology. 2024;103:e210105.
    PubMed     Abstract available
    
    
    November 2024
55. 
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e210092.
    PubMed    
    
    
    
56. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    PubMed     Abstract available
    
    
    
57. AAMODT WW, Sun C, Dahodwala N, Elser H, et al
    End-of-Life Health Care Service Use and Cost Among Medicare Decedents With Neurodegenerative Diseases.
    Neurology. 2024;103:e209925.
    PubMed     Abstract available
    
    
    
58. 
    Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy.
    Neurology. 2024;103:e209986.
    PubMed    
    
    
    October 2024
59. KIM HK, Biessels GJ, Yu MH, Hong N, et al
    SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
    Neurology. 2024;103:e209805.
    PubMed     Abstract available
    
    
    
60. YOU M, Grobois L, Etienne M
    Reader Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209374.
    PubMed    
    
    
    
61. BRENNER SR
    Reader Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209911.
    PubMed    
    
    
    
62. KRZYZANOWSKI B
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209334.
    PubMed    
    
    
    
63. LEWIS A, Galetta SL
    Editors' Note: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209851.
    PubMed    
    
    
    
64. KRZYZANOWSKI B
    Author Response: Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
    Neurology. 2024;103:e209412.
    PubMed    
    
    
    September 2024
65. SCHULZ RS, Glatz T, Buring JE, Rist PM, et al
    Migraine and Risk of Parkinson Disease in Women: A Cohort Study.
    Neurology. 2024;103:e209747.
    PubMed     Abstract available
    
    
    
66. ANASTASSIADIS C, Martinez-Valbuena I, Vasilevskaya A, Thapa S, et al
    CSF alpha-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders.
    Neurology. 2024;103:e209818.
    PubMed     Abstract available
    
    
    
67. GALLAGHER J, Gochanour C, Caspell-Garcia C, Dobkin RD, et al
    Long-Term Dementia Risk in Parkinson Disease.
    Neurology. 2024;103:e209699.
    PubMed     Abstract available
    
    
    August 2024
68. DAYAN E
    Neuropathologic Processes Linked to Brain Network Resilience in Parkinson Disease: Local or Distributed Effects?
    Neurology. 2024;103:e209731.
    PubMed    
    
    
    
69. FRIGERIO I, Broeders TAA, Lin CP, Bouwman MMA, et al
    Pathologic Substrates of Structural Brain Network Resilience and Topology in Parkinson Disease Decedents.
    Neurology. 2024;103:e209678.
    PubMed     Abstract available
    
    
    
70. DOMENIGHETTI C, Sugier PE, Ashok Kumar Sreelatha A, Schulte C, et al
    Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.
    Neurology. 2024;103:e209620.
    PubMed     Abstract available
    
    
    
71. YOU J, Wang L, Wang Y, Kang J, et al
    Prediction of Future Parkinson Disease Using Plasma Proteins Combined With Clinical-Demographic Measures.
    Neurology. 2024;103:e209531.
    PubMed     Abstract available
    
    
    
72. NISHIDA A, Shima A, Kambe D, Furukawa K, et al
    Frontoparietal-Striatal Network and Nucleus Basalis Modulation in Patients With Parkinson Disease and Gait Disturbance.
    Neurology. 2024;103:e209606.
    PubMed     Abstract available
    
    
    
73. PARNETTI L, Gaetani L
    Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases.
    Neurology. 2024;103:e209600.
    PubMed    
    
    
    
74. MERINO RUIZ MC, Mortari MR
    Neurotransmitters and Networks Interplay in Cognition and Gait Disturbances in Patients With Parkinson Disease: Beyond Lesion Localization.
    Neurology. 2024;103:e209704.
    PubMed    
    
    
    July 2024
75. YOUNG CB, Cholerton B, Smith AM, Shahid-Besanti M, et al
    The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.
    Neurology. 2024;103:e209609.
    PubMed     Abstract available
    
    
    
76. OH Y, Kim JS, Lyoo CH, Park G, et al
    Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment.
    Neurology. 2024;103:e209498.
    PubMed     Abstract available
    
    
    
77. HILKENS NA, Hammerton G, De Vries NM, Bloem BR, et al
    Guide to Decomposition of Causal Effects Into Mediation, Interaction, and Direct Effects: Case Study on Aerobic Exercise and Parkinson Disease.
    Neurology. 2024;103:e209547.
    PubMed     Abstract available
    
    
    June 2024
78. KIM S, Na HK, Sun Y, Yoon YJ, et al
    Regional Burden of Enlarged Perivascular Spaces and Cognition and Neuropsychiatric Symptoms in Drug-Naive Patients With Parkinson Disease.
    Neurology. 2024;102:e209483.
    PubMed     Abstract available
    
    
    
79. LE HERON C, Horne KL, MacAskill MR, Livingstone L, et al
    Cross-Sectional and Longitudinal Association of Clinical and Neurocognitive Factors With Apathy in Patients With Parkinson Disease.
    Neurology. 2024;102:e209301.
    PubMed     Abstract available
    
    
    
80. DI LUCA DG, Perlmutter JS
    Time for Clinical Dopamine Transporter Scans in Parkinsonism?: Not DAT Yet.
    Neurology. 2024;102:e209558.
    PubMed    
    
    
    
81. HOY CW, Chiong W
    The Ethical Landscape of Prodromal Parkinson Disease: Considerations for Shared Decision-Making and Health Equity.
    Neurology. 2024;102:e209522.
    PubMed    
    
    
    
82. HASTINGS A, Cullinane P, Wrigley S, Revesz T, et al
    Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.
    Neurology. 2024;102:e209453.
    PubMed     Abstract available
    
    
    
83. REES RN, Noyce AJ, Schrag AE
    Identification of Prodromal Parkinson Disease: We May Be Able to But Should We?
    Neurology. 2024;102:e209394.
    PubMed     Abstract available
    
    
    May 2024
84. RUS T, Cuderman A, Georgiev D
    Parkinsonism Associated With Traumatic Hemorrhage in Substantia Nigra: Role of Presynaptic Dopaminergic Imaging.
    Neurology. 2024;102:e209384.
    PubMed    
    
    
    
85. DOPPLER CEJ, Seger A, Farrher E, Regio Brambilla C, et al
    Glutamate Signaling in Patients With Parkinson Disease With REM Sleep Behavior Disorder.
    Neurology. 2024;102:e209271.
    PubMed     Abstract available
    
    
    April 2024
86. BROWN G, De Jesus S
    Bridging the Gap: Local Field Potentials Offer a Peek Into the Brain of a Person With Parkinson Disease.
    Neurology. 2024;102:e209283.
    PubMed     Abstract available
    
    
    
87. ZHAO Y, Lai Y, Konijnenberg H, Huerta JM, et al
    Association of Coffee Consumption and Prediagnostic Caffeine Metabolites With Incident Parkinson Disease in a Population-Based Cohort.
    Neurology. 2024;102:e209201.
    PubMed     Abstract available
    
    
    
88. ZHANG D, Zhou L, Lu C, Feng T, et al
    Free-Water Imaging of the Nucleus Basalis of Meynert in Patients With Idiopathic REM Sleep Behavior Disorder and Parkinson Disease.
    Neurology. 2024;102:e209220.
    PubMed     Abstract available
    
    
    
89. LAPADAT A, Nielsen SS, Racette B, Krzyzanowski B, et al
    Application of Simazine, Atrazine, and Lindane Pesticides Are Associated with Incident Parkinson's Disease Risk in the Rocky Mountain Region (S2.002).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    
90. CAMPBELL M, Grossen S, Carr E, Eid A, et al
    Precision-mapping Functional Connectivity in Parkinson Disease: Feasibility & Reliability (P7-3.005).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    
91. THOMAS E, Walker H, Middlebrooks E, McCullough B, et al
    Frameless, Virtual Cone Linac-based Stereotactic Radiosurgery for Essential & Parkinsonian Tremor: A Phase I/II Prospective Clinical Trial (S35.001).
    Neurology. 2024;102.
    PubMed     Abstract available
    
    
    March 2024
92. PARNETTI L, Paoletti FP
    Fluid Biomarkers for Trial Enrichment and Effect Monitoring in Disease-Modifying Treatments for Parkinson Disease.
    Neurology. 2024;102:e209194.
    PubMed    
    
    
    
93. HUTCHISON RM, Fraser K, Yang M, Fox T, et al
    Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial.
    Neurology. 2024;102:e209137.
    PubMed     Abstract available
    
    
    February 2024
94. TURNER RS
    Screening for Cognitive Decline in Isolated/Idiopathic REM Sleep Behavior Disorder: Which Test Is Best?
    Neurology. 2024;102:e208097.
    PubMed    
    
    
    
95. TOSIN MH, Goetz CG, Stebbins GT
    Patient With Parkinson Disease and Care Partner Perceptions of Key Domains Affecting Health-Related Quality of Life.
    Neurology. 2024;102:e208028.
    PubMed     Abstract available
    
    
    
96. COUSINS KAQ, Irwin DJ, Tropea TF, Rhodes E, et al
    Evaluation of ATN(PD) Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
    Neurology. 2024;102:e208033.
    PubMed     Abstract available
    
    
    
97. RAHAYEL S, Postuma R, Baril AA, Misic B, et al
    (99m)Tc-HMPAO SPECT Perfusion Signatures Associated With Clinical Progression in Patients With Isolated REM Sleep Behavior Disorder.
    Neurology. 2024;102:e208015.
    PubMed     Abstract available
    
    
    January 2024
98. KAHLON S, Barton CR, Abu Libdeh A, O'Malley JA, et al
    Emerging Subspecialties: Pediatric Movement Disorders Neurology.
    Neurology. 2024;102:e208050.
    PubMed     Abstract available
    
    
    December 2023
99. ELLIOTT JE, Bryant-Ekstrand MD, Keil AT, Ligman BR, et al
    Frequency of Orthostatic Hypotension in Isolated REM Sleep Behavior Disorder.
    Neurology. 2023;101:e2545-e2559.
    PubMed     Abstract available
    
    
    
100. ISHIKAWA K
     How Certain Are You When Making the Diagnosis of Multiple System Atrophy?
     Neurology. 2023;101:1081-1082.
     PubMed     Abstract available
     
     
     November 2023
101. PURNER D, Hormozi M, Weiss D, Barbe MT, et al
     Nationwide Retrospective Analysis of Combinations of Advanced Therapies in Patients With Parkinson Disease.
     Neurology. 2023 Nov 1:10.1212/WNL.0000000000207858.
     PubMed     Abstract available
     
     
     October 2023
102. KRZYZANOWSKI B, Nielsen SS, Turner JR, Racette BA, et al
     Fine Particulate Matter and Parkinson Disease Risk Among Medicare Beneficiaries.
     Neurology. 2023 Oct 30:10.1212/WNL.0000000000207871.
     PubMed     Abstract available
     
     
     
103. DARWEESH SK, Burke JF, Peters S
     Air Pollution and Parkinson Disease: Increasing Our Risk Each Breath We Take?
     Neurology. 2023 Oct 30:10.1212/WNL.0000000000207972.
     PubMed    
     
     
     
104. ROMANOWSKA J, Bjornevik K, Cortese M, Tuominen JA, et al
     Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease: A Drug-wide Association Study.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207899.
     PubMed     Abstract available
     
     
     
105. BEAUCHAMP LC, Dore V, Villemagne VL, Xu S, et al
     Utilizing (18)F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease.
     Neurology. 2023 Oct 10:10.1212/WNL.0000000000207748.
     PubMed     Abstract available
     
     
     August 2023
106. RAMATCHANDIRANE B, Rebello A, Syamala DD, Ganne P, et al
     Bilateral Iris Atrophy in a Patient With Parkinsonism.
     Neurology. 2023 Aug 30:10.1212/WNL.0000000000207743.
     PubMed    
     
     
     
107. KOSKA V, Albrecht P
     Inner Retinal Thickness Changes in Prevalent and Incident Parkinson Disease: A Potential Biomarker With Prognostic Value?
     Neurology. 2023 Aug 21:10.1212/WNL.0000000000207780.
     PubMed    
     
     
     
108. WAGNER SK, Romero-Bascones D, Cortina-Borja M, Williamson DJ, et al
     Retinal Optical Coherence Tomography Features Associated With Incident and Prevalent Parkinson Disease.
     Neurology. 2023 Aug 21:10.1212/WNL.0000000000207727.
     PubMed     Abstract available
     
     
     
109. ALTAMIMI R, Aldhalaan H, Tous E, Nicolas-Jilwan M, et al
     Teaching NeuroImages: The Putaminal Eye, A Highly Characteristic Imaging Feature of MEGDEL Syndrome.
     Neurology. 2023 Aug 21:10.1212/WNL.0000000000207823.
     PubMed    
     
     
     
110. PARNETTI L, Bellomo G
     Advances in Diagnosis and Prognosis of Parkinson Disease: Value of Cerebrospinal Fluid Proteomics.
     Neurology. 2023 Aug 16:10.1212/WNL.0000000000207724.
     PubMed    
     
     
     
111. TSUKITA K, Sakamaki-Tsukita H, Kaiser S, Zhang L, et al
     High-Throughput CSF Proteomics and Machine Learning to Identify Proteomic Signatures for Parkinson Disease Development and Progression.
     Neurology. 2023 Aug 16:10.1212/WNL.0000000000207725.
     PubMed     Abstract available
     
     
     
112. FRANKLIN GL
     A Letter From a Wise Man With Parkinson Disease.
     Neurology. 2023 Aug 1:10.1212/WNL.0000000000207660.
     PubMed    
     
     
     July 2023
113. CAMICIOLI RM, Colosimo C
     Neuropsychiatric Symptoms and Parkinson Disease: Are We Looking Carefully Enough?
     Neurology. 2023 Jul 31:10.1212/WNL.0000000000207722.
     PubMed    
     
     
     
114. LEE YG, Park M, Jeong SH, Baik K, et al
     Association of Neuropsychiatric Symptom Profiles With Cognitive Decline in Patients With Parkinson Disease and Mild Cognitive Impairment.
     Neurology. 2023 Jul 31:10.1212/WNL.0000000000207623.
     PubMed     Abstract available
     
     
     
115. BENARROCH E
     What Is the Role of the Intralaminar Thalamic Input to the Striatum and Its Potential Implications in Parkinson Disease?
     Neurology. 2023;101:118-123.
     PubMed    
     
     
     
116. AGRAWAL S, Leurgans SE, Nag S, Oveisgharan S, et al
     Effects of Cerebrovascular and Lewy Body Pathology on Parkinsonian Signs in Community-Dwelling Older Adults.
     Neurology. 2023 Jul 12:10.1212/WNL.0000000000207497.
     PubMed     Abstract available
     
     
     June 2023
117. 
     Cutaneous alpha-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease.
     Neurology. 2023 Jun 30:10.1212/WNL.0000000000207614.
     PubMed    
     
     
     
118. NELSON PT, Jicha GA
     Surprising Synergy Between Cerebrovascular and Lewy Body Disease in Parkinsonism.
     Neurology. 2023 Jun 21:10.1212/WNL.0000000000207572.
     PubMed    
     
     
     
119. ZHANG Y, Zhang Y, Mao C, Jiang Z, et al
     Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease.
     Neurology. 2023 Jun 2:10.1212/WNL.0000000000207410.
     PubMed     Abstract available
     
     
     May 2023
120. WANG L, Zhou C, Zhang W, Zhang M, et al
     Association of Cortical and Subcortical Microstructure with Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease.
     Neurology. 2023 May 18:10.1212/WNL.0000000000207408.
     PubMed     Abstract available
     
     
     
121. PORTUGAL B, Artaud F, Degaey I, Roze E, et al
     Association of Physical Activity and Parkinson Disease in Women: Long-term Follow-up of the E3N Cohort Study.
     Neurology. 2023 May 17:10.1212/WNL.0000000000207424.
     PubMed     Abstract available
     
     
     
122. CHAHINE LM, Darweesh SKL
     Physical Activity and the Risk of Parkinson Disease: Moving in the Right Direction.
     Neurology. 2023 May 17:10.1212/WNL.0000000000207527.
     PubMed    
     
     
     
123. IRANZO A, Mammana A, Munoz-Lopetegi A, Dellavalle S, et al
     Misfolded alpha-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder.
     Neurology. 2023;100:e1944-e1954.
     PubMed     Abstract available
     
     
     April 2023
124. BRUMM MC, Pierz KA, Lafontant DE, Caspell-Garcia C, et al
     Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older.
     Neurology. 2023;100:e1691-e1701.
     PubMed     Abstract available
     
     
     
125. PARNETTI L, Bellomo G
     On the Track of alpha-Synuclein in the Body: Skin Biopsies for Diagnosing Synucleinopathies?
     Neurology. 2023;100:691-692.
     PubMed    
     
     
     
126. DI LUCA DG, Luo S, Liu H, Cohn M, et al
     Racial and Ethnic Differences in Health-Related Quality of Life for Individuals with Parkinson Disease Across Centers of Excellence.
     Neurology. 2023 Apr 5:10.1212/WNL.0000000000207247.
     PubMed     Abstract available
     
     
     February 2023
127. REYNOLDS EL, Gallagher G, Hill CE, Banerjee M, et al
     Costs and Utilization of New-to-Market Neurologic Medications.
     Neurology. 2023;100:e884-e898.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum